^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Regimen: | FOLFIRI (5-fluorouracil + irinotecan + leucovorin calcium) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Published date:
11/17/2020
Excerpt:
Patients were mostly male...1.7% were BRAF mutated...Patients receiving FOLFIRI-based regimens had better outcomes than those on FOLFOX, including increased ORR (48.6% vs 34.0%) and mOS (31.3 vs 28.6 months). Higher mOS was also associated with tumors of left- rather than right-sided origin (HR 0.69 [95% CI, 0.49-0.99]), and higher ORR with liver metastases compared to all other metastases (55.4% vs 40.2%)....FOLFIRI-based cetuximab regimens were more common and showed improved outcomes over FOLFOX.
Source:
Title:
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
Excerpt:
...Patients with initial RAS mutant, BRAF wild-type left-sided mCRC....
Trial ID:
Source:
Title:
Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Excerpt:
...Expecting a minimum 20% difference (60 vs. 40%) on PFS at 12 months between groups and with the following assumptions: Alpha error (bilateral): 5% Beta error: 20% Results are reported by subgroups to compare outcome measure according to BRAF mutation. ...
Trial ID:
More C2 evidence
Source:
Title:
Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer
Excerpt:
...- Available specimens at the PCO for BRAF mutation detection...
Trial ID:
Source:
Title:
AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer
Excerpt:
...KRAS/BRAF mutant disease or KRAS wild type w/previous anti-EGFR treatment 5....
Trial ID:
Source:
Title:
Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer (CRC) with either KRAS WT or G13D mutation.
Excerpt:
...Also, in cases where the BRAF tumour status is known there must be no mutation. ...
Trial ID:
Source:
Title:
A study to explore the effects of cetuximab alone or in combination with irinotecan in patients with an abnormal gene (KRAS) in their colon cancer cells.
Excerpt:
...Prior confirmation of tumour KRAS status as either KRAS WT (with no mutations or changes in BRAF, NRAS, PIK3CA exon20) OR KRAS G13D mutation,6. ...
Trial ID:
Source:
Title:
Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer
Excerpt:
...Patients who have histologically or cytologically confirmed adenocarcinoma of the colon or rectum, excluding appendix carcinoma or anal canal carcinoma, with RAS and BRAF wild-type mutation status....
Trial ID:
Source:
Title:
An Umbrella Study to Explore Precision Treatment of Colorectal Cancer Based on Molecular Typing
Excerpt:
...Advanced colorectal cancer with genetic mutation that failed or intolerated standard treatment; Cohort 1, NGS test indicated Her2 amplification, regardless of the Her2-IHC result, regardless of the status of the Ras gene; Cohort 2, NGS test indicated Her2 mutation, non-amplified status, regardless of the Ras gene status; Cohort 3, confirmed by NGS test BRAF mutation; cohort 4, BRCA1/2 mutation confirmed by NGS test; 4. ...
Trial ID:
